BR112022014487A2 - Anticorpo bispecífico anti-pd-l1/vegf e usos do mesmo - Google Patents

Anticorpo bispecífico anti-pd-l1/vegf e usos do mesmo

Info

Publication number
BR112022014487A2
BR112022014487A2 BR112022014487A BR112022014487A BR112022014487A2 BR 112022014487 A2 BR112022014487 A2 BR 112022014487A2 BR 112022014487 A BR112022014487 A BR 112022014487A BR 112022014487 A BR112022014487 A BR 112022014487A BR 112022014487 A2 BR112022014487 A2 BR 112022014487A2
Authority
BR
Brazil
Prior art keywords
bispecific anti
antibody
vegf antibody
bispecific
antigen
Prior art date
Application number
BR112022014487A
Other languages
English (en)
Portuguese (pt)
Inventor
Wang Zhuonzhi
Chen Yunying
Li Dong
Li Jing
Original Assignee
Wuxi Biologics Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Shanghai Co Ltd filed Critical Wuxi Biologics Shanghai Co Ltd
Publication of BR112022014487A2 publication Critical patent/BR112022014487A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022014487A 2020-01-21 2021-01-19 Anticorpo bispecífico anti-pd-l1/vegf e usos do mesmo BR112022014487A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020073497 2020-01-21
PCT/CN2021/072584 WO2021147829A1 (en) 2020-01-21 2021-01-19 A bispecific anti-pd-l1/vegf antibody and uses thereof

Publications (1)

Publication Number Publication Date
BR112022014487A2 true BR112022014487A2 (pt) 2022-09-27

Family

ID=76993149

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014487A BR112022014487A2 (pt) 2020-01-21 2021-01-19 Anticorpo bispecífico anti-pd-l1/vegf e usos do mesmo

Country Status (8)

Country Link
US (1) US20230242645A1 (cg-RX-API-DMAC7.html)
EP (1) EP4093765A4 (cg-RX-API-DMAC7.html)
JP (1) JP7692422B2 (cg-RX-API-DMAC7.html)
AU (1) AU2021210025A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022014487A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165556A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021147829A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208337B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114106190B (zh) * 2020-08-31 2025-04-08 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途
CN114230669B (zh) * 2021-12-24 2024-01-30 天士力生物医药股份有限公司 一种双特异性抗体的生产方法
EP4543488A2 (en) * 2022-08-25 2025-04-30 Bright Biologics LLC Multispecific antibodies and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025256761A1 (en) * 2024-06-14 2025-12-18 BioNTech SE Combination therapy for cancer treatment
EP4766727A1 (en) * 2024-06-14 2026-07-01 Biontech SE Polytherapy for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CN106397592A (zh) * 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
CN109575140B (zh) * 2017-09-29 2021-02-23 北京比洋生物技术有限公司 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
US11827697B2 (en) * 2018-02-11 2023-11-28 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof
EP3758735B1 (en) * 2018-02-28 2023-12-13 AP Biosciences, Inc. Bifunctional proteins combining checkpoint blockade for targeted therapy
CN110305210B (zh) * 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
WO2019184909A1 (zh) * 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
CN109942712B (zh) * 2019-04-01 2022-12-20 华博生物医药技术(上海)有限公司 抗pd-l1/vegf双功能抗体及其用途
WO2021057836A1 (en) * 2019-09-25 2021-04-01 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies

Also Published As

Publication number Publication date
WO2021147829A1 (en) 2021-07-29
AU2021210025A1 (en) 2022-08-25
ZA202208337B (en) 2024-01-31
US20230242645A1 (en) 2023-08-03
CA3165556A1 (en) 2021-07-29
EP4093765A1 (en) 2022-11-30
JP7692422B2 (ja) 2025-06-13
EP4093765A4 (en) 2023-06-28
JP2023511898A (ja) 2023-03-23

Similar Documents

Publication Publication Date Title
ZA202208337B (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
MX2024000317A (es) Anticuerpos biespecificos contra calicreina y factor xii del plasma.
ECSP19010852A (es) Anticuerpos anti-pd-1, un método de producción y un método para su uso
PE20211767A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g
AR111418A1 (es) Dominios de unión a antígeno humanizados y métodos de uso
BR112019002282A2 (pt) anticorpo que se liga a pd-l1 ou um fragmento de ligação ao antígeno do anticorpo, método para produzir o mesmo e composição para prevenção ou tratamento de câncer ou doenças infecciosas
BR112022022800A2 (pt) Métodos para tratamento de mieloma múltiplo
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
CO2022008204A2 (es) Anticuerpos biparatópicos frente a cd73
GEAP202214712A (en) Pd-1-binding molecules and methods of use thereof
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
EA201691225A1 (ru) Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение
NZ611269A (en) Neutralizing anti-ccl20 antibodies
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
WO2016112078A3 (en) Anti-phf-tau antibodies and their uses
PH12022552741A1 (en) Anti-ox40 antibody and uses thereof
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
IL285308A (en) Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
MX2024014232A (es) Anticuerpo anti-b7h3 y usos del mismo
BR112022021077A2 (pt) Anticorpos humanizados antifator bb de complemento e uso dos mesmos
BR112018076247A2 (pt) anticorpos monoclonais quiméricos e humanizados para cd81
EA202190698A1 (ru) Гуманизированные анти-c5 антитела и их применение
MX2021009690A (es) Anticuerpo anti-bag2 y metodos de tratamiento del cancer.